APAlexandra Pedraza

Alexandra Pedraza

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexandra Pedraza has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mapping the Scientific Landscape of Therapeutic Apheresis: The First Comprehensive Bibliometric and Science Mapping Analysis

    by Joan Cid, Paola Charry, Alexandra Pedraza, Miquel Lozano

    Bibliometrics is the quantitative analysis of written publications. Despite the growing clinical and scientific importance of therapeutic apheresis, a comprehensive bibliometric evaluation of the field has not previously been performed. This study aimed to assess the development, collaboration patterns, citation impact, and intellectual structure of therapeutic apheresis research. A descriptive bibliometric study was conducted using PubMed, Scopus, and Web of Science Core Collection (WoS) databases. Data were retrieved on July 31, 2026. The search strategy was based on therapeutic apheresis procedures according to guidelines published by the American Society for Apheresis (ASFA). Performance analysis and science mapping were applied. VOSviewer was used for network construction and visualization. A total of 11859, 4706, and 2888 publications were identified in PubMed, Scopus, and WoS, respectively. A high degree of collaboration was observed, with > 80% of publications being multiauthored and > 80% receiving at least one citation. Average citations per publication ranged from 15.15 to 18.83. The Scopus dataset achieved an h‐index of 110 and included 45 publications cited at least 200 times. Journal of Clinical Apheresis emerged as the dominant journal in both Scopus and WoS. The cocitation analysis identified 1694 cited references receiving ≥ 5 citations. The most influential references were clinical guidelines and consensus recommendations for clinical practice. Therapeutic apheresis research has evolved into a mature, multidisciplinary, and highly collaborative scientific field. As the first comprehensive bibliometric analysis of apheresis research, this study establishes a benchmark against which future advances in the field can be measured.

  • Open Access

    Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on Infectious Complications and Immune Reconstitution According to Donor Type

    by Beatriz Merchán-Muñoz, María Suárez-Lledó, Luis Gerardo Rodríguez-Lobato, Tommaso Francesco Aiello, Antonio Gallardo-Pizarro, Paola Charry, Joan Cid, Miquel Lozano, Alexandra Pedraza, Alexandra Martínez-Roca, et al.

    Background/Objectives: This study evaluated infectious complications and immune reconstitution in 253 adults undergoing peripheral blood allogeneic hematopoietic cell transplantation (allo-HCT) with post-transplant cyclophosphamide (PTCY)-based GVHD prophylaxis. Methods: Patients received grafts from HLA-matched donors (47.4%), mismatched unrelated donors (MMUD, 33.2%), or haploidentical donors (19.4%). Results: The estimated 2-year non-relapse mortality (NRM) was 11.8%, 26.4%, and 22.4%, respectively (p = 0.0528). The cumulative incidence (Cum.Inc) of acute and chronic GVHD, immunosuppression duration, and post-transplant outcomes were similar across donor types. The day +30 Cum.Inc of bacterial bloodstream infections (BSI) tended to be higher in HLA-matched transplants (49.2%, p = 0.073), while HHV-6 reactivation showed a trend toward higher frequency in haploidentical transplants (22.4%, p = 0.068). Cytomegalovirus (CMV) reactivation occurred between days +30 and +100, with the highest Cum.Inc in MMUD (59.5%, p = 0.033). BK virus-associated hemorrhagic cystitis showed a trend toward higher incidence in MMUD (22.3%, p = 0.056). Respiratory and fungal infections were most frequent in the first 100 days, with comparable rates across donor types. By day +180, most patients achieved immune reconstitution, with normalization of CD4+ T cells, CD8+ T cells, and IgG levels, independent of donor type. Conclusions: Patients undergoing allo-HCT with PTCY-based prophylaxis experience a high infectious density rate early post-transplant, which decreases after 6 months as immune reconstitution progresses, regardless of donor type.


  • Open Access

    Reduced Dose of Post-Transplant Cyclophosphamide with Tacrolimus for the Prevention of Graft-versus-Host Disease in HLA-Matched Donor Peripheral Blood Stem Cell Transplants: A Prospective Pilot Study

    by Alex Juárez, María Queralt Salas, Alexandra Pedraza, María Suárez-Lledó, Luís Gerardo Rodríguez-Lobato, María Teresa Solano, Anna Serrahima, Meritxell Nomdedeu, Joan Cid, Miquel Lozano, et al.

    PTCY 50 mg/kg/day on days +3/+4 is an excellent strategy to prevent GVHD. However, its use is associated with adverse outcomes such as delayed engraftment, increased risk of infection, and cardiac complications. This pilot study evaluates the efficacy and toxicity of a reduced dose of PTCY (40 mg/kg/day) combined with tacrolimus in 22 peripheral blood HLA-matched alloHSCT patients. At day +100, the cumulative incidences of grade II–IV and III–IV acute GVHD were 18.2% and 4.5%, respectively. No grade IV acute GVHD or steroid-refractory disease was observed. The cumulative incidences of all-grade and moderate-severe chronic GVHD at 1-year were 11.4% and 6.4%, respectively. No patient died from transplant-related complications. Two-year OS and RFS were 77.1% and 58.3%, respectively. All patients engrafted, with neutrophil and platelet recovery occurring at a median of 15 (IQR 14–16) and 16 days (IQR 12–23), respectively. The cumulative incidences of bloodstream bacterial infections, polyomavirus BK hemorrhagic cystitis, HHV6 reactivation, CMV reactivation, and fungal infections were 13.6%, 9.1%, 9.1%, 4.6%, and 6%, respectively. Only one early cardiac event was observed. These results suggest that PTCY 40 mg/kg/day on a +3/+4 schedule provides adequate immunosuppression to allow for engraftment and prevent clinically significant GVHD with a low toxicity profile.


  • Open Access

    At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program

    by Sonia Ruiz-Boy, Alexandra Pedraza, Marta Prat, Maria Queralt Salas, Esther Carcelero, Gisela Riu-Viladoms, María Suárez-Lledó, Inés Monge-Escartín, Luis Gerardo Rodríguez-Lobato, Alexandra Martínez-Roca, et al.

    Cytomegalovirus (CMV) infection is a relevant cause of morbimortality in patients receiving allogeneic stem cell transplantation (allo-HCT). Foscarnet (FCN) is an effective drug against CMV administered intravenously and usually on an inpatient basis. The Home Care Unit (HCU) for hematologic patients at our hospital designed an at-home FCN administration model to avoid the hospitalization of patients requiring FCN treatment. This study analyzes whether the at-home administration of FCN is as safe and effective as its hospital administration. We collected and compared demographic, clinical, analytical, and economic data of patients with CMV infection post-allo-HCT who received FCN in the hospital (n = 16, 17 episodes) vs. at-home (n = 67, 88 episodes). The proportions of patients with cured CMV infections were comparable between the two groups (65.9% vs. 76.5%, p = 0.395). The median duration of FCN treatment was 15 (interquartile range [IQR] 9–23) and 14 (IQR 11–19) days in the HCU and inpatient cohorts, respectively (p = 0.692). There were no significant differences in the FCN toxicities between groups except for hypocalcemia (26.1% vs. 58.8%, p = 0.007), which was more prevalent in the inpatient cohort. A significant cost-effectiveness was found in the HCU cohort, with a median savings per episode of EUR 5270. It may be concluded that home administration of FCN is a safe, effective, and cost-efficient therapeutic option for patients with CMV infection and disease.


  • Top Cited Papers
    Open Access

    Easix Score Correlates With Endothelial Dysfunction Biomarkers and Predicts Risk of Acute Graft-Versus-Host Disease After Allogeneic Transplantation

    by Alexandra Pedraza, María Queralt Salas, Luis Gerardo Rodríguez-Lobato, Silvia Escribano-Serrat, María Suárez-Lledo, Nuria Martínez-Cebrian, María Teresa Solano, Jordi Arcarons, Laura Rosiñol, Gonzalo Gutiérrez-García, et al.


  • Open Access

    Effect of CD34+ Cell Dose on the Outcomes of Allogeneic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide

    by Alexandra Pedraza, María Queralt Salas, Luis Gerardo Rodríguez-Lobato, Paola Charry, María Suárez-Lledo, Nuria Martínez-Cibrian, Ariadna Doménech, Maria Teresa Solano, Jordi Arcarons, Noemí de Llobet, et al.


  • Open Access

    Impact of Early Intrapatient Variability of Tacrolimus Concentrations on the Risk of Graft-Versus-Host Disease after Allogeneic Stem Cell Transplantation Using High-Dose Post-Transplant Cyclophosphamide

    by Daniel N. Marco, María Queralt Salas, Gonzalo Gutiérrez-García, Inés Monge, Gisela Riu, Esther Carcelero, Joan Ramón Roma, Noemí Llobet, Jordi Arcarons, María Suárez-Lledó, et al.

    Tacrolimus (Tac) is a pivotal immunosuppressant agent used to prevent graft-versus-host disease (GVHD) after allogeneic stem cell transplantation (alloHSCT). Tac is characterized by a narrow therapeutic window and a high inter-patient and intra-patient pharmacokinetic variability (IPV). Although high IPV of Tac concentrations has been associated with adverse post-transplant outcomes following solid organ transplantation, the effects of Tac IPV on alloHSCT recipients have not been determined. Tac IPV was therefore retrospectively evaluated in 128 alloHSCT recipients receiving high-dose post-transplant cyclophosphamide (PTCy) and the effects of Tac IPV on the occurrence of acute GVHD (aGVHD) were analyzed. Tac IPV was calculated from pre-dose concentrations (C0) measured during the first month after Tac initiation. The cumulative rates of grades II-IV and grades III-IV aGVHD at day +100 were 22.7% and 7%, respectively. Higher Tac IPV was associated with a greater risk of developing GVHD, with patients having IPV > 50th percentile having significantly higher rates of grades II-IV (34.9% vs. 10.8%; hazard ratio [HR] 3.858, p < 0.001) and grades III-IV (12.7% vs. 1.5%; HR 9.69, p = 0.033) aGVHD than patients having IPV ≤ 50th percentile. Similarly, patients with IPV > 75th percentile had higher rates of grades II-IV (41.9% vs. 16.5%; HR 3.30, p < 0.001) and grades III-IV (16.1% vs. 4.1%; HR 4.99, p = 0.012) aGVHD than patients with IPV ≤ 75th percentile. Multivariate analyses showed that high Tac IPV (>50th percentile) was an independent risk factor for grades II-IV (HR 2.99, p = 0.018) and grades III-IV (HR 9.12, p = 0.047) aGVHD. Determination of Tac IPV soon after alloHSCT could be useful in identifying patients at greater risk of aGVHD.